Efficacy and Tolerance of Solriamfetol in Idiopathic Hypersomnia: A Randomized, Double-Blind, Placebo-Controlled Trial

The primary objective of this study is to evaluate the **efficacy** and **tolerance** of solriamfetol in patients diagnosed with **idiopathic hypersomnia**. This condition is characterized by excessive daytime sleepiness and prolonged nighttime sleep, which significantly impacts daily functioning and quality of life. Assessing the efficacy of solriamfetol is clinically relevant as it may offer a therapeutic option to improve wakefulness and reduce the burden of symptoms in affected individuals. The study is designed as a randomized, double-blind, placebo-controlled trial to ensure robust and reliable results.

The clinical trial involves participants diagnosed with **idiopathic hypersomnia**. The study population includes both male and female subjects, with an age range of 18 to 64 years. The general health status of participants is not specified, and the total number of participants is not provided as the sponsor did not give this information. The trial population was selected without targeting any vulnerable groups. There are no specific lifestyle considerations such as diet, physical activity, or habits mentioned for this study. Key inclusion or exclusion criteria are not detailed in the available data.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** study to evaluate the efficacy and tolerance of solriamfetol in patients diagnosed with **idiopathic hypersomnia**. The trial is categorized as a Phase 4 study and is expected to commence recruitment on July 15, 2024, with an estimated completion date of December 15, 2026. The trial will involve multiple study visits, beginning with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. Following successful inclusion, participants will be randomly assigned to receive either solriamfetol or a placebo, ensuring the double-blind nature of the study is maintained.

Participants will be required to attend regular follow-up visits throughout the trial duration. These visits are designed to monitor the participants' response to the treatment, assess any adverse effects, and ensure adherence to the study protocol. The frequency and specific timing of these follow-up visits will be determined by the study protocol. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the primary and secondary endpoints of the study.

The expected length of participant involvement will span the entire trial duration, from the initial screening to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The study aims to provide valuable insights into the treatment of idiopathic hypersomnia, contributing to the understanding of solriamfetol's efficacy and safety profile in this patient population.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. As the trial is in Phase 4, it focuses on post-marketing surveillance to gather additional information on the drug's effectiveness and safety in a larger population. The trial is scheduled to commence recruitment on July 15, 2024, and is estimated to conclude by December 15, 2026. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical assessments in Phase 4 trials may include monitoring of **biomarker** levels, symptom improvement scores, or disease remission rates. Data collection and analysis will likely involve validated scales, laboratory tests, and possibly patient-reported outcomes, conducted at predetermined intervals throughout the trial duration. The trial's findings will contribute to a comprehensive understanding of the drug's performance in real-world settings.